title: [Effects of micronized fenofibrate on lipid and uric acid metabolism in patients with hyperlipidemia].
abstract: OBJECTIVE
  To evaluate the efficacy and safety of micronised fenofibrate on lipid and uric acid metabolism in patients with hyperlipidemia.
  
  
  METHODS
  A total of 116 patients with hypertriglyceridemia and hyperuricemia received 200 mg micronised fenofibrate for 4 weeks. Physical and laboratory investigations of lipid profiles, serum uric acid, and 24 h urine uric acid, for adverse effects were assessed.
  
  
  RESULTS
  (1) Serum triglyceride (TG) was significantly reduced by 51%, whilst high density lipoprotein cholesterol (HDL-C) increased 24% after 4-week fenofibrate treatment. Moreover, serum total cholesterol (TC) and low density lipoprotein cholesterol (LDL-C) were reduced by 10% and 12%, respectively. (2) Serum uric acid levels were significantly reduced by 28.3% [from (462.8+/-73.5) micromol/L to (320.1+/-83.0) micromol/L] after fenofibrate treatment, independent of baseline uric acid levels. There was no difference in serum uric acid changes between male gender and female gender(29.8% and 25.1%, respectively). (3) Urine uric acid levels were increased by 36.0% [from (2 874.2+/-503.4) micromol/L to (3 604.2+/-769.7) micromol/L]. The urine uric acid changes were 41.1% in male gender group and 33.4% in female gender group. The uric acid clearance/creatinin clearance ratio was increased in all cases after treatment.
  
  
  CONCLUSIONS
  Micronised fenofibrate treatment could significantly improve lipid and uric acid metabolism in patients with hypertriglyceridemia and hyperuricemia, and is generally safe and well tolerated. The anti-hyperuricemic effect of fenofibrate is a result of increasing the urinary excertion of uric acid, independent of baseline level and gender.
authors.affiliation: Department of Cardiology, People's Hospital of Peking University, Beijing 100044, China.
authors.forename: Li Jun
authors.initials: LJ
authors.lastname: Li
authors.forename: Hong
authors.initials: H
authors.lastname: Chen
authors.forename: Jing Yi
authors.initials: JY
authors.lastname: Ren
authors.forename: Lan
authors.initials: L
authors.lastname: Wang
authors.forename: Yu
authors.initials: Y
authors.lastname: Luo
mesh_terms: D000328:Adult; D000368:Aged; D005260:Female; D011345:Fenofibrate / Q000627:therapeutic use*; D006801:Humans; D006949:Hyperlipidemias / Q000150:complications / Q000188:drug therapy*; D033461:Hyperuricemia / Q000150:complications / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D014280:Triglycerides / Q000097:blood*; D014527:Uric Acid / Q000097:blood*
chemical_list: D000960:Hypolipidemic Agents; D008055:Lipids; D014280:Triglycerides; D014527:Uric Acid; D011345:Fenofibrate